In the closing segment, the panel looks ahead, both at where the technology is heading and at what will still require human judgment once it gets there. Piotr Alvarez outlines a three-horizon view of artificial intelligence’s (AI) impact on peptide method development. In the near term, he expects AI to narrow the range of conditions…
